Salute e Benessere
Regarding rumors of an imminent approval of lecanemab in Great Britain: BioArctic
Oskar Bosson , VP Communications and IR
E-mail: oskar.bosson@bioarctic.se
Phone: +46 70 410 71 80
BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with BioArctic's partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further information, please visit www.bioarctic.com.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/bioarctic/r/regarding-rumors-of-an-imminent-approval-of-lecanemab-in-great-britain,c4027253
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/regarding-rumors-of-an-imminent-approval-of-lecanemab-in-great-britain-bioarctic-302228385.html